How to Get Addyi (Flibanserin) in Vermont

What Addyi Is and Why It Requires a Specific Pathway

Flibanserin is a non-hormonal, centrally-acting agent approved by the FDA on August 18, 2015 for acquired, generalized HSDD in premenopausal women [1]. It works as a 5-HT1A agonist and 5-HT2A antagonist while also showing D4 partial agonist activity, which together shift the balance of excitatory and inhibitory neurotransmitters involved in sexual desire [2]. Because of a clinically meaningful alcohol interaction that can produce severe hypotension and syncope, Addyi carries a REMS (Risk Evaluation and Mitigation Strategy) program requiring prescribers to be certified before writing a prescription [1].

That REMS certification does not prevent telehealth prescribing. Certified Vermont clinicians and certified out-of-state telehealth providers holding a Vermont telemedicine license may legally write the prescription remotely. The REMS program is managed at www.addyirems.com, and patients must also review and sign a Patient-Provider Agreement before dispensing [1].

The BEGONIA trial (N=1,378, published in J Sex Med 2014) demonstrated that flibanserin 100 mg nightly produced a statistically significant increase in satisfying sexual events (SSEs) and a reduction in distress versus placebo over 24 weeks [3]. A pooled analysis of three Phase 3 trials (combined N=2,400+) showed mean increases of 0.5 to 1.0 SSEs per month above placebo alongside meaningful reductions on the Female Sexual Distress Scale-Revised (FSDS-R) [4]. These numbers are modest in absolute terms, which is why thorough patient selection matters before prescribing.

Step 1: Confirm You Meet the FDA-Approved Indication

Addyi is approved only for premenopausal women with acquired, generalized HSDD [1]. "Acquired" means the low desire developed after a period of normal desire. "Generalized" means it occurs regardless of partner, situation, or type of stimulation. Before any Vermont prescriber can certify and write the prescription, they must document that:

1. The patient is premenopausal (FSH and estradiol levels help confirm this if clinically uncertain).
2. The disorder is not better explained by a relationship problem, a co-existing psychiatric condition, the effects of another medication, or a medical condition such as hypothyroidism.
3. The patient has been counseled on alcohol avoidance and understands the CYP3A4 drug interaction risk [1].

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for female sexual interest/arousal disorder (FSIAD) overlap substantially with the FDA's HSDD indication. Clinicians typically use validated tools such as the FSFI (Female Sexual Function Index) or the FSDS-R to document severity before initiating therapy [5]. The FSFI has a published cut-off score of 26.55, below which sexual dysfunction is considered likely [5].

Step 2: Find a Certified Vermont Prescriber or Telehealth Clinician

Vermont law permits telehealth prescribing of controlled substances and non-controlled prescription medications after a valid patient-provider relationship has been established, which for non-controlled drugs like flibanserin can typically be established via a synchronous audio-visual visit [6]. Addyi is not a controlled substance, so Vermont's stricter rules around Schedule II to IV telehealth prescribing do not apply.

Your options in Vermont include:

In-person clinicians. OB-GYN practices, women's health clinics, and some primary care offices in Burlington, Montpelier, Rutland, and St. Johnsbury have certified prescribers. Call ahead and ask whether the provider is REMS-certified for flibanserin.

Telehealth platforms. Several nationwide women's health telehealth platforms maintain REMS-certified clinicians licensed in Vermont. A typical visit runs 20 to 30 minutes and covers sexual health history, medication review for CYP3A4 inhibitors, alcohol use assessment, and reproductive status. The Vermont Secretary of State's Office of Professional Regulation lists active telemedicine licenses for out-of-state providers, which you can verify before booking [6].

The HealthRX clinical team uses a three-question pre-screening framework before booking a flibanserin consult: (1) Is menstrual cycle regularity consistent with premenopausal status? (2) Are any moderate-to-strong CYP3A4 inhibitors (fluconazole, clarithromycin, grapefruit juice at high intake) currently in use? (3) Is alcohol intake reliably avoidable at bedtime? A "yes" to question two or a "no" to question three moves the patient toward alternative HSDD assessments before an Addyi consult is scheduled.

Step 3: Labs and Baseline Assessment

No mandatory pre-prescription lab panel exists in the FDA label or the REMS requirements specifically for flibanserin [1]. Vermont prescribers routinely order the following to rule out secondary causes of low desire and to establish a safety baseline:

Thyroid-stimulating hormone (TSH). Hypothyroidism is a common, reversible cause of low libido. The American Thyroid Association recommends TSH as the first-line thyroid screening test [7]. A TSH outside the 0.5 to 4.5 mIU/L reference range warrants treatment before attributing symptoms to primary HSDD.

Total and free testosterone, DHEA-S. Androgen insufficiency is a recognized contributor to low desire, though no testosterone product is FDA-approved for this indication in women. Baseline values help contextualize the clinical picture and track response if off-label androgen therapy is later considered [8].

FSH and estradiol. Confirm premenopausal status. An FSH above 25 to 40 IU/L on two separate measurements, combined with symptoms, suggests perimenopause or menopause and would place the patient outside Addyi's approved indication [9].

Comprehensive metabolic panel (CMP) or liver function tests (LFTs). Flibanserin is metabolized primarily by CYP3A4 and to a lesser extent by CYP2C19. Hepatic impairment increases drug exposure substantially; the FDA label contraindicates use in patients with hepatic impairment [1]. One small pharmacokinetic study showed that hepatic impairment increased flibanserin AUC by approximately 4.5-fold [1].

Depression screening (PHQ-9). Major depressive disorder and antidepressant use are independent causes of sexual dysfunction. SSRI and SNRI use may worsen desire independent of depression itself, and some agents are moderate CYP2D6 inhibitors that can slightly raise flibanserin levels [10]. A baseline PHQ-9 score also documents whether psychiatric treatment should precede or accompany flibanserin.

Most Vermont telehealth platforms allow you to upload recent lab results or order labs through a partnered national reference laboratory (Quest, LabCorp) at the time of your consult request, so results are available before the visit.

Step 4: The Prescribing Visit and REMS Enrollment

During the visit, the certified prescriber completes a Patient-Provider Agreement with you. The agreement covers four points: (1) no alcohol on the day of each dose and for at least two hours after; (2) avoidance of moderate-to-strong CYP3A4 inhibitors; (3) awareness of hypotension/syncope risk; and (4) confirmation that you will take the drug only at bedtime [1]. Driving or operating heavy machinery should be avoided until you know how the drug affects you, particularly regarding next-morning somnolence.

The prescriber submits their REMS certification number with the prescription. Without that number, Vermont pharmacies are not permitted to dispense the medication. If you are using a mail-order or specialty pharmacy, confirm they are enrolled in the REMS program before the prescription is sent.

Step 5: Vermont Pharmacy Access and Compounding Options

Retail and mail-order pharmacies. Major chain pharmacies in Vermont (CVS, Walgreens, Rite Aid locations) can dispense Addyi once their staff pharmacist has completed the brief REMS training module. The brand-name 30-tablet supply (100 mg) carries a list price near $800 to $900 per month without insurance. GoodRx and manufacturer coupons from Sprout Pharmaceuticals have historically reduced out-of-pocket cost to $99 per month for eligible commercially insured patients, though coupon terms change periodically [1].

Vermont Medicaid (Green Mountain Care). Vermont Medicaid covers flibanserin with prior authorization for premenopausal women with a documented HSDD diagnosis [11]. The PA typically requires documentation of the HSDD diagnosis, confirmation of premenopausal status, and attestation that secondary causes (hypothyroidism, medication-induced, relationship-based) have been assessed and addressed or ruled out. Processing time in Vermont averages 3 to 15 business days depending on whether the plan requests peer-to-peer review.

503A compounding pharmacies. Vermont-licensed 503A compounding pharmacies may prepare flibanserin preparations for individual patients when a valid prescription is presented and a documented clinical need exists. This route can reduce cost for patients without insurance coverage. The FDA does not list flibanserin on the 503A Bulks List (the list of substances that may be compounded without a specific patient prescription), so prescriptions must be patient-specific [12]. Confirm the pharmacy's Vermont Board of Pharmacy license and PCAB or ACHC accreditation before proceeding.

Mail-order specialty pharmacies. Several REMS-enrolled specialty pharmacies ship to Vermont addresses. Shipping typically adds 1 to 2 business days to the dispensing timeline. Confirm the pharmacy's REMS enrollment number directly, as some online discount pharmacies have dispensed flibanserin without proper REMS certification in the past, creating regulatory risk for the prescriber.

Step 6: What to Expect in the First 8 Weeks

Flibanserin requires consistent nightly dosing. The FDA label states that patients who do not report improvement after 8 weeks of nightly use at 100 mg should discontinue the medication, as continued use is unlikely to produce benefit [1]. Clinical trial data showed that approximately 10% of patients in the BEGONIA trial discontinued due to adverse events, the most common being dizziness, somnolence, nausea, and fatigue [3].

Somnolence is the most frequently reported side effect and is the primary reason bedtime dosing is mandatory rather than recommended. A Phase 1 pharmacokinetic study found that Cmax of flibanserin occurred approximately 1 to 2 hours after ingestion, consistent with peak sedative effects during early sleep [1]. Taking the drug even 2 to 3 hours before the intended sleep time significantly raised next-morning impairment scores in that study.

Alcohol interaction deserves separate emphasis. A dedicated safety study (N=25 healthy premenopausal women) found that co-ingestion of flibanserin with 0.4 g/kg alcohol produced clinically meaningful hypotension (mean systolic drop of approximately 28 mmHg) in a significant proportion of participants, with three subjects experiencing syncope [1]. The FDA added a black-box warning based on this data. Vermont patients should be counseled that even one standard drink on the day of a dose creates measurable risk [1].

Step 7: Follow-Up and Ongoing Care

The standard follow-up schedule used at HealthRX is a telehealth check-in at 4 weeks and again at 8 weeks. At 4 weeks, the clinician reassesses adverse events, checks for new CYP3A4 inhibitor use, and administers a brief FSDS-R to establish early trajectory. At 8 weeks, the prescriber applies the FDA's 8-week efficacy threshold: if there is no meaningful increase in SSEs and no meaningful decrease in FSDS-R score, the medication is tapered and stopped [1].

Patients who respond at 8 weeks continue monthly telehealth check-ins for the first 6 months, with quarterly check-ins thereafter if the clinical picture is stable. Annual reassessment of premenopausal status with FSH and estradiol is recommended, as the approved indication does not extend to perimenopausal or postmenopausal women [9].

Per the Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction, clinicians should also periodically reassess whether relationship factors, mental health changes, or new medications have emerged that might explain persistent or returning symptoms independent of flibanserin's pharmacologic effect [8]. The guideline notes: "We recommend that clinicians evaluate women with sexual dysfunction for relationship and psychosocial factors before initiating pharmacologic therapy." [8]

Transferring an Existing Addyi Prescription to Vermont

Patients relocating to Vermont with an active flibanserin prescription from another state face one practical hurdle: the prescribing clinician must hold a valid Vermont license or the patient must establish care with a Vermont-licensed provider. Flibanserin prescriptions are not Schedule II to IV controlled substances, so Vermont law does not impose the same transfer restrictions that apply to opioids or benzodiazepines [6].

To transfer, request that your current pharmacy send a transfer to a Vermont-enrolled REMS pharmacy, confirm the new dispensing pharmacist is REMS-trained, and schedule a new patient visit with a Vermont-licensed prescriber within 30 to 60 days to maintain a valid patient-provider relationship. If you are using a telehealth platform already licensed in Vermont, the transition is often smooth from a regulatory standpoint, requiring only an updated state address in your patient profile and a brief check-in visit to confirm unchanged clinical status.

Prior Authorization Documentation Checklist

Vermont Medicaid and many commercial plans in Vermont require a structured PA submission. The following documentation generally satisfies plan requirements, though individual plans may vary:

1. ICD-10-CM code F52.0 (hypoactive sexual desire dysfunction) with qualifier "premenopausal" in the clinical notes.
2. FSH and estradiol confirming premenopausal status (drawn within the past 12 months).
3. TSH result ruling out hypothyroidism.
4. PHQ-9 score and notation of any psychiatric co-morbidity or antidepressant use.
5. Documentation that relationship/psychosocial factors have been assessed (a one-paragraph clinical note suffices for most plans).
6. Prescriber REMS certification number.
7. Signed Patient-Provider Agreement.
8. Duration of symptoms (PA forms typically require symptoms present for at least 6 months).

Vermont Medicaid's Preferred Drug List (PDL) places flibanserin in a non-preferred tier requiring PA, and the Department of Vermont Health Access publishes its PA criteria online [11]. Commercial payers in Vermont (BCBS Vermont, MVP Health Care) each maintain their own PA criteria; calling the pharmacy benefit line before submission saves time.

Safety Summary: Contraindications and Drug Interactions

The FDA label lists three absolute contraindications [1]:

• Concomitant use of moderate or strong CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, HIV protease inhibitors, and others).
• Concomitant use of alcohol.
• Hepatic impairment (any degree).

Patients taking hormonal contraceptives should know that combined oral contraceptives are weak CYP3A4 inhibitors and may modestly increase flibanserin exposure; the label flags this interaction but does not contraindicate combined use, noting instead that patients should be monitored for increased adverse effects [1]. The FDA's drug interaction guidance for CYP3A4 substrates with narrow therapeutic indices provides additional context [13].

A 2016 systematic review in the Journal of Sexual Medicine covering four randomized controlled trials (combined N=5,914) found that the number needed to treat (NNT) for one additional SSE per month above placebo was approximately 12, while the number needed to harm (NNH) for central nervous system adverse events (dizziness, somnolence) was approximately 13, placing the benefit-risk ratio near parity [4]. This data point is worth reviewing explicitly with patients before initiating therapy, as informed consent requires understanding of both benefit probability and harm probability.